Sign inJoin waitlistJoin the waitlist

JB

Julia Bender

Vice Chair for Clinical Research · New York Presbyterian Hospital

Credentials: · · · ·

History

New York Presbyterian Hospital
Present
Clinical Research) · New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
1995–1996
Mount Sinai Medical Center
1992–1995
The Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania
1988–1992

Research

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an…
The Lancet Oncology · 2020 · 268 citations
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
Nature Communications · 2022 · 209 citations
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study
Journal of Clinical Oncology · 2008 · First of 17 authors · Corresponding · 204 citations

Steven DuBois
24 papers
Andrew Kung
17 papers
Katherine Janeway
16 papers · 1 as a fellow
Brenda Weigel
13 papers
FC
Filemon Cruz
13 papers
NS
Neerav Shukla
12 papers
Michael Ortiz
11 papers
Brian Crompton
10 papers
ES
Emily Slotkin
10 papers
AeRang Kim
9 papers
Darrell Yamashiro
9 papers
Elizabeth Fox
9 papers

Clinical trials

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2017–2024
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Principal investigator · Completed · Phase 1
Children's Oncology Group
2015–2024
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
Principal investigator · Completed · Phase 1
New Approaches to Neuroblastoma Therapy Consortium
2009–2019
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2009